This partnership marks Apollo’s sixth agreement with a research institution.
Apollo Therapeutics and the University of Oxford have formed a drug discovery and development collaboration to translate groundbreaking work by Oxford biomedical researchers into practical applications.
As part of the agreement, Apollo will identify and evaluate new and validated therapeutic targets from Oxford researchers that have the potential to become important new drugs, while Oxford researchers will have access to treatment development expertise and program funding from Apollo.
Apollo’s drug discovery experts support the development of new medicines across areas such as oncology, immunology and inflammatory diseases, helping to identify the medicines with the greatest potential to transform standards of care globally.
In addition, program funding from Apollo will improve patient access to clinical trials and help Oxford researchers bring new medicines to market faster.
Commenting on the collaboration, Peter Kyle, Secretary of State for Science, Innovation and Technology at the University of Oxford, said: “Working together, Apollo and the University of Oxford, will deliver new medicines to tackle diseases such as cancer and autoimmune diseases, potentially saving thousands of lives.”
Dr Mhairi Gibbs, Chief Executive of Oxford University Innovation, commented: “With the support of Oxford University Innovation’s research commercialisation team and our investment partners, we hope to accelerate the development of more life-saving medicines to help patients who need them most.”
This latest collaboration marks Apollo’s sixth agreement with a university or academic research center, further strengthening its scalable research and development platform for drug discovery and development.
“We are now working with six of the world’s leading universities and research centers to transform standards of care in key commercial markets, building on the breakthroughs in biology and basic medical research being made by scientists at these institutions,” said Apollo Chief Executive Officer Dr. Richard Mason.
Other research institutions include the University of Cambridge, Imperial College London, University College London, King’s College London and the Institute of Cancer Research.
